Skip to Content
Merck
  • Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.

Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer.

Endocrine-related cancer (2017-04-27)
Siker Kimbung, Ching-Yi Chang, Pär-Ola Bendahl, Laura Dubois, J Will Thompson, Donald P McDonnell, Signe Borgquist
ABSTRACT

The impact of systemic 27-hydroxycholesterol (27HC) and intratumoral CYP27A1 expression on pathobiology and clinical response to statins in breast cancer needs clarification. 27HC is an oxysterol produced from cholesterol by the monooxygenase CYP27A1, which regulates intracellular cholesterol homeostasis. 27HC also acts as an endogenous selective estrogen receptor (ER) modulator capable of increasing breast cancer growth and metastasis. 27HC levels can be modulated by statins or direct inhibition of CYP27A1, thereby attenuating its pro-tumorigenic activities. Herein, the effect of statins on serum 27HC and tumor-specific CYP27A1 expression was evaluated in 42 breast cancer patients treated with atorvastatin within a phase II clinical trial. Further, the associations between CYP27A1 expression with other primary tumor pathological features and clinical outcomes were studied in two additional independent cohorts. Statin treatment effectively decreased serum 27HC and deregulated CYP27A1 expression in tumors. However, these changes were not associated with anti-proliferative responses to statin treatment.

MATERIALS
Product Number
Brand
Product Description

Avanti
27-hydroxycholesterol (D6), Avanti Research - A Croda Brand
Sigma-Aldrich
4-(Dimethylamino)phenyl isocyanate, 97%
Avanti
Sphingosine (d17:1), Avanti Research - A Croda Brand LM2000, ethanol solution